Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Durvalumab in Indian Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer (NSCLC)

NCT04416633 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04416633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04416633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Durvalumab in Indian Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2021
Completion date
October 27, 2023
Enrollment
100 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable non-small cell lung cancer (nsclc)